China’s largest taurine producer of Yongan pharmaceutical industry sued for suspected patent infring-tom365.com

Yongan, China’s largest producer of taurine, was sued for suspected patent infringement, Beijing daily (reporter Fang Binnan Wang Xiaoli), the largest taurine producer in China, Yongan pharmaceutical industry may face great resistance to performance. Recently, the Yongan pharmaceutical announced that the company’s fist product taurine involving overseas patent litigation, may have an important impact on the company. Yongan pharmaceutical said that the company in the United States New Jersey District Court for patent infringement was prosecuted. The plaintiff said Yongan pharmaceutical taurine products infringe the "450 patent" and "patent 451 patent", mainly for the new manufacturing process of taurine, and request a permanent injunction to prohibit the court, related party infringes the patent right, and make corresponding compensation. For this, the Yongan pharmaceutical industry said it is not clear that the other party mentioned in the proceedings of the "new manufacturing process" specific circumstances and the corresponding details. At present, the company is preparing to respond to the corresponding procedures. Although there is no doubt about the success of Xiao Yongan pharmaceutical in this lawsuit, some investors have expressed concern about it, which is directly related to the product structure of Yongan pharmaceutical industry. The latest semi annual report shows that the revenue source of Yongan pharmaceutical industry is divided into three parts: pharmaceutical manufacturing, health care products and chemical supplies. Among them, the pharmaceutical sector only taurine a product, revenue accounted for 80% of total revenue. Among the other two plates, industrial ethylene oxide is one of the Yongan pharmaceutical industry’s investment projects, the main purpose is to protect the supply of raw materials for taurine production. At present, the total ethylene oxide market oversupply, long-term production and sales upside down, the project continued losses, revenue fell 51% over the previous year. And the share of health care products in the overall revenue is low, only 7.8%. It is worth noting that the U.S. market involved in the lawsuit is particularly important for the Yongan pharmaceutical industry. Semi annual report shows that, Yongan pharmaceutical revenue, the overseas market revenue accounted for 65% of the total revenue of enterprises. The United States and Japan are an important place for export of enterprise products. Yongan pharmaceutical also said that if the overseas lawsuit lost, may have an important impact on the company. As the product structure is too single, Yongan pharmaceutical industry has begun to try the layout of health industry in recent years, but just entered the "pay tuition."". In June this year, Yongan pharmaceutical responsible for the production of health products, a wholly-owned subsidiary of Yongan health due to add contraband ingredients in the product, was reported and completely off the shelf. In the sideline progress difficult at the moment, encountered the main product lawsuit, in worse circumstances underground, if lost, Yongan pharmaceutical undoubtedly bear greater pressure on performance. (source: Beijing business daily) go into Sina Finance shares

国内最大牛磺酸生产永安药业商遭起诉 涉嫌专利侵权   北京商报讯(记者 方彬楠 王潇立)国内最大的牛磺酸生产商永安药业可能会面临极大的业绩阻力。近日,永安药业公告称,公司的拳头产品牛磺酸涉及境外专利诉讼,可能会对公司产生重要影响。永安药业表示,公司在美国新泽西地区地方法院因涉嫌专利侵权被起诉。原告称永安药业的牛磺酸产品侵犯了美国的“450专利”和“451专利”,专利内容主要为牛磺酸的新型制造工艺,并向法院请求永久禁令,禁止相关方侵犯上述专利权,并要求做出相应补偿。   对于此事,永安药业方面表示尚不清楚对方在诉讼中提及的“新型制造工艺”的具体情况及相应细节。目前公司正在准备相应的应诉手续。   尽管尚不知晓永安药业在这场官司中的胜算,但已经有投资者对此表示担忧,而这与永安药业的产品结构直接相关。最新的半年报显示,永安药业的营收来源分为三部分:医药制造、保健品和化工用品等。其中,医药制造板块只有牛磺酸一种产品,收入占据总营收的80%。其他两个板块中,工业用环氧乙烷是永安药业的募投项目之一,主要目的是为了保障牛磺酸生产原料的供应。目前,环氧乙烷市场总体供过于求,产销长期倒挂,该项目持续发生亏损,营收同比上年下滑51%。而保健品目前在整体营收中所占份额较低,仅为7.8%。   值得注意的是,此次官司涉及的美国市场对于永安药业来讲分外重要。半年报显示,永安药业的营收中,海外市场的收入占据企业总营收的65%。而美国和日本则是企业产品出口的重要落点。永安药业也表示,若这场境外官司败诉,可能会对公司产生重要的影响。   由于产品结构过于单一,永安药业在近年开始尝试健康产业方面的布局,但刚刚入行就“交了学费”。今年6月,永安药业负责保健品生产的全资子公司永安康健因在产品中添加违禁成分,遭到举报并全面下架。在副业进展吃力的当下遭遇主营产品官司,在雪上加霜的境地下,如果败诉,永安药业无疑承受着较大的业绩压力。(来源:北京商报) 进入【新浪财经股吧】讨论相关的主题文章:

« »

Comments closed.